Total Funding
3
Total FundingSeries C raised
Growth Score
pts
Heat Score
-53 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
321836
Atterx develops therapeutics to fight the growing epidemic of antibiotic resistant bacteria.
H. Thomas Watkins: DirectorPast Role: Human Genome Sciences, President & CEO
Richard Burgess: Co-Founder
About the Company
Atterx is developing fundamentally new therapeutics to combat the growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon's core technology is a new way to kill unwanted and even multi-drug resistant bacteria.
The company is
located in the MG&E Innovation Center in the University Research Park in Madison, Wisconsin.
